The Pharmacology of Moclobemide and its Fatal Drug Interactions in Overdose

REFERENCES

• Richards J.G., Saura J., Ulrich J., and Da Prada M. Molecular neuroanatomy of monoamine oxidases in human brainstem. Psychopharmocology (Berl) 106 Suppl: S21–3 (1992).
   Google Scholar
• Fitton A., Faulds D.% and Goa K.L. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43(4): 561–96 (1992). (Published errata appear in Drugs 1992 Sep; 44(3): 374 and 1993 June; 45(6): 894).
   Google Scholar
• Ramasubbu R. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression. J Psychiatry Neurosci 24(1): 45–50 (1999).
   PubMedGoogle Scholar
• Montejo-Gonzalez A.L., Llorca G., Izquierdo J.A., Ledesma A., Bousono M., Calcedo A., Carrasco J.L., Ciudad J., Daniel E., De la Gandara J., Derecho J., Franco M., Gomez M.J., Macias J.A., Martin T., Perez V., Sanchez J.M., Sanchez S. and Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23(3): 176–94 (1997).
   PubMedGoogle Scholar
• Philipp M., Kohnen R. and Benkert O. A comparison study of moclobemide and doxepine in major depression with special reference to effects on sexual dysfunction. Int Clin Psychopharmacol 7(3–4): 149–53 (1993).
   PubMedGoogle Scholar
• Manerix™ (Moclobemide) Product Monograph, Control #053631 Hoffman LaRoche, Mississauga, Ontario, Feb. 1999.
   Google Scholar
• Kettler R., Da Prada M. and Burkard W.P. Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr. Scand. Suppl. 360P: 101–2 (1990).
   Google Scholar
• Freeman H. Drug profile—Moclobemide. Lancet. 342: 1528–1532 (1993).
   PubMedGoogle Scholar
• Dingemanse J., Wood N., Guentert T., Oie S. Ouwerkerk M. and Amrein R. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmocology (Berl) 140(2): 164–72 (1998).
   Google Scholar
• Finberg J.P. Pharmacology of reversible and selective inhibitors of monoamine oxidase type A. Acta Psychiatr Scand Suppl; 386: 8–13 (1995).
   Google Scholar
• Nair N.P., Ahmed S.K. and Kin N.M. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide. J Psychiatry Neurosci 18(5): 214–25 (1993).
   PubMedGoogle Scholar
• Haefely W., Burkard W.P., Cesura A., Colzi A., Kettler R., Lorez H.P., Martin J.R., Moreau J.L., Richards J.G., Schaffner R., et al. Pharmacology of moclobemide. Clin Neuropharmacol 16 Suppl 2: S8–18 (1993).
   Google Scholar
• Burkard W.P., Da Prada M., Keller H.H., Kettler R. and Haefely W. (Hoffman-La Roche) Pre-clinical pharmacology of moclobemide. A review of published studies. Br J Psychiatry Suppl (6): 84–8 (1989).
   PubMedGoogle Scholar
• Stoeckel K., Pfefen J.P., Mayersohn M., Schoerlin M.P., Andressen C., Ohnhaus E.E., Frey F. and Guentert T.W. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand Suppl 360: 94–7 (1990).
   Google Scholar
• Schoerlin M.P., Horber F.F., Frey F.J., Mayersohn M. Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function. J Clin Pharmacol 30(3): 272–84 (1990).
   PubMedGoogle Scholar
• Waldmeier PC, Amrein R., Schmid-Burgk W. Pharmacology and Pharmacokinetics of brofaromine and moclobemide in animals and humans. In Kennedy SH (ed) Clinical Advances in Monoamine Oxidase Inhibitor Therapies. American Psychiatric Press, Wash DC. pp. 33–59 (1994).
   Google Scholar
• Singer P.P. and Jones G.R. An uncommon fatality due to moclobemide and paroxetine. J Anal Toxicol 21(6): 518–20 (1997).
   Google Scholar
• Myrenfors P.G., Eriksson T., Sandstedt C.S. and Sjoberg G. Moclobemide overdose. J. Intern. Med. 233: 113–115 (1993).
   PubMed Web of Science ®Google Scholar
• Hetzel W. Safety of moclobemide taken in overdose for attempted suicide. Psychophamacology 106: S127-S129 (1992).
   Google Scholar
• Iwersen S. and Schmoldt A. Three Suicide Attempts with Moclobemide. Clinical Toxicology 34: 223–225 (1996).
   Google Scholar
• Camaris C. and Little D. A fatality due to moclobemide. J Forensic Sci. 42(5): 954–5 (1997).
   PubMedGoogle Scholar
• Gaillard Y., Pepin G. Moclobemide fatalities: report of two cases and analytical determinations by GC-MS and HPLC-PDA after solid-phase extraction. Forensic Sci Int 23; 87(3): 239–48 (1997).
   Google Scholar
• Hernandez A.F., Montero M.N., Pia A. and Villanueva E. Fatal moclobemide overdose or death caused by serotonin syndrome? J. Forensic Sci. 40: 128–130 (1995).
   PubMed Web of Science ®Google Scholar
• Neuvonen P.J., Pohjola-Sintonent S., Tacke U. and Vuori E. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342: 1419 (1993).
   PubMed Web of Science ®Google Scholar
• Ferrer-Dufol A., Perez-Aradros C., Murillo E.C., Marques-Alamo J.M. Fatal serotonin syndrome caused by moclobemide-clomipramine overdose. J Toxicol Clin Toxicol; 36(1–2): 31–2 (1998).
   PubMedGoogle Scholar
• Mcintyre I.M., King C.V., Staikos V., Gall J. and Drummer O.H. A fatality involving moclobemide, sertraline, and pimozide. J Forensic Sci; 42(5): 951–3 (1997).
   PubMedGoogle Scholar
• Power B.M., Pinder M., Hackett L.P. Ilett K.F. Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine. Anaesth Intensive Care; 23(4): 499–502 (1995).
   Google Scholar
• Drummer O.H. Moclobemide Interaction with Other Antidepressants. TIAFT Bulletin 28(4) 7–9 (1998).
   Google Scholar
• Sternbach H. The serotonin syndrome. Am. J. Psychiatry. 148: 705–713 (1991).
   PubMed Web of Science ®Google Scholar
• Skop, B.P., Finkelstein J.A., Mareth T.R., Magoon M.R. and Brown T.M. The serotonin syndrome associated with paroxetine, an over-the-counter cold remedy, and vascular disease. Am J Emerg Med. Nov; 12(6): 642–4 (1994).
   PubMedGoogle Scholar